388 related articles for article (PubMed ID: 27566796)
1. Familial chilblain lupus due to a gain-of-function mutation in STING.
König N; Fiehn C; Wolf C; Schuster M; Cura Costa E; Tüngler V; Alvarez HA; Chara O; Engel K; Goldbach-Mansky R; Günther C; Lee-Kirsch MA
Ann Rheum Dis; 2017 Feb; 76(2):468-472. PubMed ID: 27566796
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Clinical Response to Janus Kinase Inhibition in Patients With Familial Chilblain Lupus and TREX1 Mutation.
Zimmermann N; Wolf C; Schwenke R; Lüth A; Schmidt F; Engel K; Lee-Kirsch MA; Günther C
JAMA Dermatol; 2019 Mar; 155(3):342-346. PubMed ID: 30673078
[TBL] [Abstract][Full Text] [Related]
3. Familial chilblain lupus due to a novel mutation in TREX1 associated with Aicardi-Goutie'res syndrome.
Yi C; Li Q; Xiao J
Pediatr Rheumatol Online J; 2020 Apr; 18(1):32. PubMed ID: 32293470
[TBL] [Abstract][Full Text] [Related]
4. Familial Chilblain Lupus - What Can We Learn from Type I Interferonopathies?
Fiehn C
Curr Rheumatol Rep; 2017 Aug; 19(10):61. PubMed ID: 28844088
[TBL] [Abstract][Full Text] [Related]
5. [Familial chilblain lupus: Four cases spanning three generations].
Beltoise AS; Audouin-Pajot C; Lucas P; Tournier E; Rice GI; Crow YJ; Mazereeuw-Hautier J
Ann Dermatol Venereol; 2018 Nov; 145(11):683-689. PubMed ID: 30217686
[TBL] [Abstract][Full Text] [Related]
6. Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3' repair exonuclease 1 (TREX1).
Günther C; Berndt N; Wolf C; Lee-Kirsch MA
JAMA Dermatol; 2015 Apr; 151(4):426-31. PubMed ID: 25517357
[TBL] [Abstract][Full Text] [Related]
7. Deregulated type I IFN response in TREX1-associated familial chilblain lupus.
Peschke K; Friebe F; Zimmermann N; Wahlicht T; Schumann T; Achleitner M; Berndt N; Luksch H; Behrendt R; Lee-Kirsch MA; Roers A; Günther C
J Invest Dermatol; 2014 May; 134(5):1456-1459. PubMed ID: 24270665
[No Abstract] [Full Text] [Related]
8. Methods of Assessing STING Activation and Trafficking.
Pokatayev V; Yan N
Methods Mol Biol; 2017; 1656():167-174. PubMed ID: 28808969
[TBL] [Abstract][Full Text] [Related]
9. A Novel Type I Interferon Primed Dendritic Cell Subpopulation in TREX1 Mutant Chilblain Lupus Patients.
Eugster A; Müller D; Gompf A; Reinhardt S; Lindner A; Ashton M; Zimmermann N; Beissert S; Bonifacio E; Günther C
Front Immunol; 2022; 13():897500. PubMed ID: 35911727
[TBL] [Abstract][Full Text] [Related]
10. A homozygote TREX1 mutation in two siblings with different phenotypes: Chilblains and cerebral vasculitis.
Kisla Ekinci RM; Balci S; Bisgin A; Altintas DU; Yilmaz M
Eur J Med Genet; 2017 Dec; 60(12):690-694. PubMed ID: 28919362
[TBL] [Abstract][Full Text] [Related]
11. Familial chilblain lupus--a monogenic form of cutaneous lupus erythematosus due to a heterozygous mutation in TREX1.
Günther C; Meurer M; Stein A; Viehweg A; Lee-Kirsch MA
Dermatology; 2009; 219(2):162-6. PubMed ID: 19478477
[TBL] [Abstract][Full Text] [Related]
12. Type I interferonopathies with novel compound heterozygous TREX1 mutations in two siblings with different symptoms responded to tofacitinib.
Zhang S; Song J; Yang Y; Miao H; Yang L; Liu Y; Zhang X; Liu Y; Wang T
Pediatr Rheumatol Online J; 2021 Jan; 19(1):1. PubMed ID: 33407657
[TBL] [Abstract][Full Text] [Related]
13. Systemic involvement in TREX1-associated familial chilblain lupus.
Günther C; Hillebrand M; Brunk J; Lee-Kirsch MA
J Am Acad Dermatol; 2013 Oct; 69(4):e179-81. PubMed ID: 24034389
[No Abstract] [Full Text] [Related]
14. Exonuclease TREX1 degrades double-stranded DNA to prevent spontaneous lupus-like inflammatory disease.
Grieves JL; Fye JM; Harvey S; Grayson JM; Hollis T; Perrino FW
Proc Natl Acad Sci U S A; 2015 Apr; 112(16):5117-22. PubMed ID: 25848017
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency.
Briand C; Frémond ML; Bessis D; Carbasse A; Rice GI; Bondet V; Duffy D; Chatenoud L; Blanche S; Crow YJ; Neven B
Ann Rheum Dis; 2019 Mar; 78(3):431-433. PubMed ID: 30282666
[No Abstract] [Full Text] [Related]
16. TREX-1-Related Disease Associated with the Presence of Cryofibrinogenemia.
Paradis C; Cadieux-Dion M; Meloche C; Gravel M; Paradis J; Des Roches A; Leclerc G; Cossette P; Begin P
J Clin Immunol; 2019 Jan; 39(1):118-125. PubMed ID: 30685859
[TBL] [Abstract][Full Text] [Related]
17. Autosomal dominant inheritance of a heterozygous mutation in SAMHD1 causing familial chilblain lupus.
Ravenscroft JC; Suri M; Rice GI; Szynkiewicz M; Crow YJ
Am J Med Genet A; 2011 Jan; 155A(1):235-7. PubMed ID: 21204240
[No Abstract] [Full Text] [Related]
18. Heterozygous TREX1 p.Asp18Asn mutation can cause variable neurological symptoms in a family with Aicardi-Goutieres syndrome/familial chilblain lupus.
Abe J; Izawa K; Nishikomori R; Awaya T; Kawai T; Yasumi T; Hiragi N; Hiragi T; Ohshima Y; Heike T
Rheumatology (Oxford); 2013 Feb; 52(2):406-8. PubMed ID: 22829693
[No Abstract] [Full Text] [Related]
19. Familial chilblain lupus in a child with heterozygous mutation in SAMHD1 and normal interferon signature.
Linggonegoro DW; Song H; Jones KM; Lee PY; Schmidt B; Vleugels RA; Huang JT
Br J Dermatol; 2021 Sep; 185(3):650-652. PubMed ID: 33887057
[No Abstract] [Full Text] [Related]
20. Brief Report: Blockade of TANK-Binding Kinase 1/IKKɛ Inhibits Mutant Stimulator of Interferon Genes (STING)-Mediated Inflammatory Responses in Human Peripheral Blood Mononuclear Cells.
Frémond ML; Uggenti C; Van Eyck L; Melki I; Bondet V; Kitabayashi N; Hertel C; Hayday A; Neven B; Rose Y; Duffy D; Crow YJ; Rodero MP
Arthritis Rheumatol; 2017 Jul; 69(7):1495-1501. PubMed ID: 28426911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
